PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer

Cancer Biomark. 2022;34(2):251-264. doi: 10.3233/CBM-210335.

Abstract

Gastric cancer (GC) is a common cancer with high mortality and morbidity rates worldwide. Although medical and surgical treatments have improved, the mechanisms of the progression of GC remain unclear. Platelet-derived growth factor receptor-β (PDGFRB) plays a pivotal role in angiogenesis and tumor cell proliferation and has been suggested as a prognostic marker of cancer. This study aimed to explore the relationship of PDGFRB expression with clinicopathologic characteristics, immune cell infiltration status, and prognosis in GC. In this study, we visualized the expression and prognostic values of PDGFRB in GC using the Oncomine, UALCAN, GEPIA, and Kaplan-Meier Plotter databases. And then we explored the potential relationships between PDGFRB expression and the levels of immune cell infiltration using the TIMER, GEPIA databases and CIBERSORT algorithm. Furthermore, LinkedOmics analysis was performed to explore the functions for PDGFRB. The results showed close correlations between PDGFRB and immune cell infiltration especially M2 Macrophage infiltration in GC. High PDGFRB expression was related to poor outcomes in GC. High PDGFRB expression can negatively affect GC prognosis by promoting angiogenesis and modulating the tumor immune microenvironment. These results strongly suggest that PDGFRB can be used as a prognostic biomarker of GC and provide novel insights into possible immunotherapeutic targets.

Keywords: Gastric cancer; PDGFRB; bioinformatics; prognostic biomarker.

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Humans
  • Prognosis
  • Receptor, Platelet-Derived Growth Factor beta / genetics
  • Stomach Neoplasms* / metabolism
  • Tumor Microenvironment

Substances

  • Biomarkers, Tumor
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta